TRENDFINDERS- Scanning Board for Charts and Stocks

[Gd2Aussie3]

Press Release Source: Signalife, Inc.

Signalife Receives Another $3.3 Million Sales Orders

Tuesday September 25, 2007

LOS ANGELES, Sept. 25 /PRNewswire-FirstCall/ -- Earlier today, Signalife announced that it has received additional orders for the sale of $3.3 million (three million three hundred thousand dollars) of Fidelity 100 units as a continued result of new management’s initial sales campaign.
In the words of Signalife’s President, Dr. Harmison, “that is $5.28 million of sales orders of our Fidelity 100 since I took over operational control of the Company, and – as we fulfill our existing orders – the Company will continue its efforts and expects to add additional sales to the system shortly.”
About Signalife:
Signalife, Inc. is an award-winning life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting. Signalife is
publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://Signalife.com. Clear Data. Trusted Results.
Caution Regarding Forward-Looking Statements:
Statements in this release that are not strictly historical are "forward-looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete
the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the
unavailability of financing to complete management's plans and objectives,including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities an Exchange
Commission.

Contact: Kevin Kading for Signalife, Inc., (212)-918-4606
Source: Signalife, Inc.
---------------------
G' day Mates,

Aussie